JP2015221809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015221809A5 JP2015221809A5 JP2015134900A JP2015134900A JP2015221809A5 JP 2015221809 A5 JP2015221809 A5 JP 2015221809A5 JP 2015134900 A JP2015134900 A JP 2015134900A JP 2015134900 A JP2015134900 A JP 2015134900A JP 2015221809 A5 JP2015221809 A5 JP 2015221809A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- disease
- antigenic composition
- composition according
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 230000000890 antigenic effect Effects 0.000 claims 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 11
- 239000002502 liposome Substances 0.000 claims 11
- 230000004064 dysfunction Effects 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 239000000232 Lipid Bilayer Substances 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000003252 repetitive effect Effects 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 108010033276 Peptide Fragments Proteins 0.000 claims 2
- 102000007079 Peptide Fragments Human genes 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 208000018282 ACys amyloidosis Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000002939 deleterious effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000007087 memory ability Effects 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16116509P | 2009-03-18 | 2009-03-18 | |
| US61/161,165 | 2009-03-18 | ||
| US25602809P | 2009-10-29 | 2009-10-29 | |
| US61/256,028 | 2009-10-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500251A Division JP2012520852A (ja) | 2009-03-18 | 2010-03-18 | 治療的使用のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015221809A JP2015221809A (ja) | 2015-12-10 |
| JP2015221809A5 true JP2015221809A5 (enExample) | 2016-02-25 |
Family
ID=42376556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500251A Withdrawn JP2012520852A (ja) | 2009-03-18 | 2010-03-18 | 治療的使用のための方法 |
| JP2015134900A Pending JP2015221809A (ja) | 2009-03-18 | 2015-07-06 | 治療的使用のための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500251A Withdrawn JP2012520852A (ja) | 2009-03-18 | 2010-03-18 | 治療的使用のための方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20100285108A1 (enExample) |
| EP (2) | EP2408807B1 (enExample) |
| JP (2) | JP2012520852A (enExample) |
| KR (1) | KR20120004994A (enExample) |
| CN (1) | CN102428101B (enExample) |
| AU (1) | AU2010224824B2 (enExample) |
| CA (1) | CA2755683A1 (enExample) |
| DK (1) | DK2408807T3 (enExample) |
| ES (1) | ES2885398T3 (enExample) |
| HU (1) | HUE055739T2 (enExample) |
| IL (1) | IL214919A (enExample) |
| MX (1) | MX2011009654A (enExample) |
| PT (1) | PT2408807T (enExample) |
| RU (1) | RU2579659C2 (enExample) |
| SG (1) | SG174871A1 (enExample) |
| SI (1) | SI2408807T1 (enExample) |
| WO (1) | WO2010106127A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CN106390107B (zh) * | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| AU2013205313B2 (en) * | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
| MY164376A (en) * | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2811188C (en) * | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| KR101981351B1 (ko) | 2011-10-07 | 2019-09-02 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
| RU2644242C2 (ru) | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| CN104428411B (zh) * | 2012-05-08 | 2018-11-23 | 健康科学西部大学 | 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台 |
| WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
| CN107073297B (zh) | 2014-07-08 | 2021-09-14 | 纽约大学 | Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途 |
| RU2689689C2 (ru) * | 2015-01-23 | 2019-05-28 | Хеликс Байофарма Корпорейшн | Конъюгаты антитело-уреаза для терапевтических целей |
| WO2017027685A2 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CN111787942B (zh) | 2017-10-25 | 2024-03-29 | 杨森制药公司 | 磷酸化Tau肽的组合物及其用途 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| MY206596A (en) | 2019-02-08 | 2024-12-25 | Janssen Pharmaceuticals Inc | Method of safe administration of phosphorylated tau peptide vaccine |
| JOP20210284A1 (ar) * | 2019-04-24 | 2023-01-30 | Janssen Pharmaceuticals Inc | الإعطاء غير المتجانس للقاحات تاو |
| SG11202112329RA (en) * | 2019-05-21 | 2021-12-30 | Ac Immune Sa | Anti-abeta vaccine therapy |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| AU2024211543A1 (en) | 2023-01-26 | 2025-07-17 | Ac Immune Sa | Liposomal construct |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7408027B1 (en) * | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| WO1994013795A1 (en) * | 1992-12-14 | 1994-06-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| AU5508798A (en) * | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| JP2004503747A (ja) * | 2000-07-11 | 2004-02-05 | モレキュラー ジェリアトリクス コーポレイション | 結合物質の同定するための試薬と方法 |
| AU2003292936A1 (en) | 2002-12-24 | 2004-07-22 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| EP1494000A1 (en) * | 2003-07-02 | 2005-01-05 | Sicpa Holding S.A. | Method of marking a material with ions already comprised in said material and method of verifying the authenticity of said material |
| US20050261475A1 (en) * | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| HUE025186T2 (en) * | 2004-02-20 | 2016-02-29 | Ac Immune Sa | Methods and methods using supramolecular constructs |
| KR101152557B1 (ko) * | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція |
-
2010
- 2010-03-18 HU HUE10710017A patent/HUE055739T2/hu unknown
- 2010-03-18 DK DK10710017.4T patent/DK2408807T3/da active
- 2010-03-18 CN CN201080021554.XA patent/CN102428101B/zh active Active
- 2010-03-18 EP EP10710017.4A patent/EP2408807B1/en active Active
- 2010-03-18 WO PCT/EP2010/053519 patent/WO2010106127A2/en not_active Ceased
- 2010-03-18 ES ES10710017T patent/ES2885398T3/es active Active
- 2010-03-18 EP EP21180474.5A patent/EP3978517A1/en active Pending
- 2010-03-18 RU RU2011141889/10A patent/RU2579659C2/ru active
- 2010-03-18 JP JP2012500251A patent/JP2012520852A/ja not_active Withdrawn
- 2010-03-18 KR KR1020117024550A patent/KR20120004994A/ko not_active Ceased
- 2010-03-18 CA CA2755683A patent/CA2755683A1/en not_active Abandoned
- 2010-03-18 PT PT107100174T patent/PT2408807T/pt unknown
- 2010-03-18 AU AU2010224824A patent/AU2010224824B2/en active Active
- 2010-03-18 SI SI201032083T patent/SI2408807T1/sl unknown
- 2010-03-18 SG SG2011067097A patent/SG174871A1/en unknown
- 2010-03-18 MX MX2011009654A patent/MX2011009654A/es active IP Right Grant
- 2010-03-18 US US12/661,628 patent/US20100285108A1/en not_active Abandoned
-
2011
- 2011-09-01 IL IL214919A patent/IL214919A/en active IP Right Grant
-
2015
- 2015-07-06 JP JP2015134900A patent/JP2015221809A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015221809A5 (enExample) | ||
| RU2011141889A (ru) | Способ для применения в терапии | |
| JP2012520852A5 (enExample) | ||
| BRPI0619747B8 (pt) | método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide | |
| CL2011002457A1 (es) | Peptido antigenico fosforilado de una proteina tau presente en la superficie de un liposoma; composicion farmaceutica que comprende el peptido antigeno tau en la superficie de un liposoma; uso para preparar un medicamento para tratar trastorno o enfermedad neurodegenerativa . | |
| Davtyan et al. | Immunogenicity of DNA-and recombinant protein-based Alzheimer disease epitope vaccines | |
| Jagessar et al. | Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant | |
| AU2021200093B2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| KR20200143422A (ko) | 항-aveta 치료적 백신 | |
| Kafami et al. | Methadone diminishes neuroinflammation and disease severity in EAE through modulating T cell function | |
| JP2014531455A5 (enExample) | ||
| CN110691599B (zh) | 使用脂多糖的脑功能改善剂、食品和药品 | |
| Mohajeri et al. | Prevention of age-associated dementia | |
| PE20252196A1 (es) | Anticuerpos anti-beta amiloide n3pglu, dosis y usos de estos | |
| WO2014176149A4 (en) | Treatment of alzheimer's and cognitive impairment with andrographolides | |
| JP2022533422A5 (enExample) | ||
| KR102506460B1 (ko) | 알츠하이머병（ａｄ）의 치료 및 예방 | |
| WO2015165980A2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| US20240226097A1 (en) | Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors | |
| KR102388363B1 (ko) | 알츠하이머병（ａｄ）의 치료 및 예방 | |
| WO2010035261A3 (en) | Amyloid beta-peptides and methods of use thereof | |
| Marciani | Development of an effective Alzheimer’s vaccine | |
| Arruda et al. | Primary lateral sclerosis: a case report with spect study | |
| Wilcock | The pharmacological treatment of Alzheimer's disease with cholinesterase inhibitors and memantine | |
| Diniz et al. | SMART syndrome: a late reversible complication of radiotherapy |